Kathrin C. Meyer, PhD, studied cellular and biomedical Sciences at the Institute of Cell Biology in Berne, Switzerland. Her postdoctoral research was performed in Brian Kaspar’s laboratory at the Center for Gene Therapy in Columbus, Ohio. During that time, Dr. Meyer established a new and fast reprogramming method for in vitro modeling of neurodegenerative diseases using patient skin cells. Moreover, Dr. Meyer developed intrathecal gene therapy programs for several neurodegenerative diseases, including Spinal Muscular Atrophy, SMARD1/CMT2S and Batten Disease. Multiple clinical trials that are based on this work are currently ongoing at Nationwide Children’s Hospital. In 2017, Dr. Meyer became a Principal Investigator at Nationwide Children’s Hospital. She is also an Assistant Professor in the Department of Pediatrics at The Ohio State University, Columbus, Ohio.

Mr. Anand is the founder of Alcyone Therapeutics and its predecessor Alcyone Lifesciences, and serves as the CEO. For more than 25 years in the life science industry, Mr. Anand has overseen the lab-to-clinic translational process of next-generation treatments for a range of conditions including end-stage kidney disease, peripheral vascular disease, orthopedic disorders, and CNS disorders including brain cancer, as well as diagnostics. He holds hundreds of patents and has expertise in the convergence of drugs and devices: he is the founder of Anuncia, Inc., a company focused on treatment and management of CSF dysfunction and the co-founder and Chairman of Arthromeda, Inc., a company focused on developing an A.I. based, patient-specific navigation platform for orthopedic applications. Before founding Alcyone Lifesciences and Arthromeda, Mr. Anand was a founding executive member of WMR Biomedical (now Arsenal Medical & Lyra Therapeutics) where he was responsible for key strategic funding transactions.

In 2010, Dr. Nicolas Wein received his PhD in molecular biology in the laboratory of Nicolas Levy, MD, PhD, at the Marseille Medical School in France, where he worked on the development of new diagnosis tools for neuromuscular diseases, the discovery of the Minidysferlin and its use for gene transfer, and investigation of the use of exon-skipping for dysferlinopathies. In 2011, he joined the team of Kevin Flanigan, MD, principal investigator in The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, as a postdoctoral scientist. Dr. Wein worked on the identification of a novel IRES in the dystrophin gene and on an out-of-frame exon-skipping approach that can benefit patients with 5’ mutations in the DMD gene. He, Dr. Flanigan and Dr. Waldrop initiated a clinical trial for this subpopulation of patient in early 2020. In 2016 he opened his lab and continued working on neuromuscular disorders such as Duchenne Muscular dystrophy and neurological disorders. His lab has built on his expertise in translational research. His lab continues to integrate basic science and gene therapy skills in order to advance understanding and treatment of the neurological and muscular disorders. His team long-term projects focus on RNA and DNA editing and gene transfer as therapies using adeno-associated virus and U7snRNA, a small nuclear RNA (RNA editing tool) as well as the CRISPR/Cas9 (DNA editing tool).

Deep leads R&D, business, and strategy for Alcyone’s Precision Drug Delivery. Deep was part of the founding team at Alcyone and has over 15 years broad experience in precision delivery technology R&D, CSF and CNS transport sciences, regulatory and clinical affairs, business and corporate development, and alliance management. Deep holds several patents and publications in precision delivery and CSF management. Previously, Deep worked at Accellent (now Integer) in medical technology R&D, manufacturing, and global program management. Deep has also worked at Abbott Bioresearch (now AbbVie) in manufacturing process development, as well as Heamonetics in R&D. Deep has a BS in Biomedical Engineering with a minor in Material Sciences from Worcester Polytechnic Institute, and a Certificate in Project Management from Boston University.

Dr. Coletta leads business operations and strategic planning for Alcyone Therapeutics. Previously, Dr. Coletta was a member of the executive leadership team at Coactuate, a strategic design consultancy, and the Drug Delivery Innovation and Strategy Lead at Amgen. Before joining Amgen, Dr. Coletta was an Engagement Manager with McKinsey & Company, advising pharmaceutical and medical device clients on strategy development, organizational structure redesign, efficiency program design and implementation, and due diligence of acquisition targets. He started his career as a Drug Discovery Chemist at Pfizer’s Groton site. Dr. Coletta received his PhD in organic chemistry from Harvard University and his BS in chemistry from the University of Illinois.

Dr. Martin leads the Alcyone Therapeutics – Falcon™ Platform Research, Data Sciences and Bioinformatics group focused on advancement of our Precision Delivery portfolio. Dr. Martin has 20 years of experience in CSF mechanics and physiology, has co-authored/authored over 70 peer-reviewed journal publications and book chapters in the field, and currently serves as Associate Editor of Fluids and Barriers of the CNS (Springer/Nature). Prior to joining Alcyone Therapeutics, Dr. Martin was Associate Professor of Chemical and Biological Engineering at University of Idaho, the Principal Investigator for research funded by NIH, NASA, the National Science Foundation (NSF), the biotechnology industry (such as Genentech, Biogen, Voyager Therapeutics and others), and foundations (such as the American Syringomyelia and Chiari Alliance Project), and consulted about medical devices and CNS drug delivery for more than 10 years. He completed his postdoctoral fellowship in bioengineering and biomechanical engineering at the Swiss Federal Institute of Technology under Professor N. Stergiopulos and served as the first Director of the Conquer Chiari Research Center at The University of Akron. Dr. Martin earned a PhD in mechanical engineering from the University of Illinois at Chicago.

Andrew leads the engineering device development team and coordinates multifunctional groups across the organization with a focus on advancement of the Alcyone Therapeutics Precision Delivery portfolio. Andrew has over 20 years of experience bringing innovative technologies from concept to market, through regulatory clearance and product launch. Andrew first joined Alcyone to lead the development of a Hydrocephalus shunt technology, known as ReFlow, which was spun out to form Anuncia Inc. in 2018. Prior to joining Alcyone Therapeutics, Andrew held positions at Accellent Inc. (now Integer) and Ranfac Corporation. Andrew holds numerous patents on a wide range of product families spanning over 20 years of cutting-edge technology development. Andrew holds a BS in Mechanical Engineering, and certificates in Medical Device Regulatory Affairs from Northeastern University and in Medical Device Management from Worcester Polytechnic Institute.

Greg leads our Human Resources function by defining the people and culture strategy for Alcyone as well as creating an infrastructure to support a high performing organization. Greg has over 25 years of Human Resources experience in both emerging and commercialized life sciences companies. Previously Greg held human resources positions at Seres Therapeutics, Sunovion Pharmaceuticals, Medidata Solutions, and Biogen where he led HR Operations, Compensation, Talent Acquisition, International Assignments Program, and specialized in the building and development of talent and leadership.

Greg has a Bachelor of Science degree in Human Resources Management from the University of Massachusetts Boston, and a Master of Education degree from Lesley University.